Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 25019569)


A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM.

Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11.


A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A.

Eur J Cancer. 2014 Sep;50(14):2408-16. doi: 10.1016/j.ejca.2014.06.010. Epub 2014 Jul 15.


Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.

Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.


Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J.

Cochrane Database Syst Rev. 2013 Jul 9;7:CD006910. doi: 10.1002/14651858.CD006910.pub2. Review.


[Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].

Malkowska-Walczak B, Nowak-Markwitz E, Spaczyński M.

Ginekol Pol. 2009 Sep;80(9):682-6. Polish.


Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.

J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.


A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.


A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.

Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.

Am J Clin Oncol. 2008 Oct;31(5):476-80. doi: 10.1097/COC.0b013e31816a6221.


A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.

Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS.

Oncotarget. 2014 Nov 30;5(22):11154-67.


Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.

Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr.

J Hematol Oncol. 2010 Mar 11;3:9. doi: 10.1186/1756-8722-3-9.


Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.

Ichikawa R, Torii Y, Oe S, Kawamura K, Kato R, Hasegawa K, Udagawa Y.

Arch Gynecol Obstet. 2014 Nov;290(5):979-84. doi: 10.1007/s00404-014-3268-7. Epub 2014 May 6.


Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025.


Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S; ASSIST-1 Study Group.

Eur J Cancer. 2009 Sep;45(13):2324-32. doi: 10.1016/j.ejca.2009.05.016. Epub 2009 Jun 8.


Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.


Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero A.

Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17.


Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.

Rapoport BL, Vorobiof DA, Slabber C, Alberts AS, Hlophe HS, Mohammed C.

Int J Gynecol Cancer. 2009 Aug;19(6):1137-41. doi: 10.1111/IGC.0b013e3181a8b938.


Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G.

J Clin Oncol. 2013 Nov 10;31(32):4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30.


Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.

Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology.

Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. doi: 10.1007/s00280-008-0909-1. Epub 2009 Jan 21.


Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.

Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C.

Anticancer Drugs. 2008 Jun;19(5):541-5. doi: 10.1097/CAD.0b013e3282fcbbf7.


Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.

Ann Oncol. 2012 May;23(5):1185-9. doi: 10.1093/annonc/mdr441. Epub 2011 Oct 5.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk